Charles River Laboratories International, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 30, 2023; comparisons are to the year ended December 31, 2022. Fiscal 2022 included a 53rd week, which affects year-over-year comparability. The company provides research models, drug discovery and safety assessment services, and manufacturing support to life-sciences clients.
Financial results and liquidity
- Revenue: $4.129 billion, up 3.9% from $3.976 billion. Service revenue rose 6.9% to $3.440 billion; product revenue declined 9.2% to $689.4 million.
- Profitability: Operating income was $617.3 million, down 5.2%; operating margin fell to 14.9% from 16.4%. Net income attributable to common shareholders was $474.6 million, down from $486.2 million. Diluted EPS was $9.22 versus $9.48.
- Cash flow and investment: Operating cash flow was $683.9 million, compared with $619.6 million. Capital expenditures were $318.5 million. Investing activities used $563.2 million, including acquisitions; financing activities used $85.5 million.
- Cash and liquidity: Cash and cash equivalents were $276.8 million at year-end. The company says available funds, operating cash flow and financing access are sufficient for the foreseeable future. Its $3.0 billion revolving credit facility had $1.129 billion drawn and matures in April 2026.
- Debt: Borrowings under the revolving facility and senior notes totaled $2.629 billion; total debt and finance leases were $2.667 billion. The weighted-average debt interest rate was 4.93%. The company reported compliance with its credit-facility covenants.
- Other obligations: Unconditional purchase obligations totaled approximately $390 million, mostly expected to be settled in 2024. Operating and finance lease liabilities were $474.1 million and $28.6 million, respectively.
Segments and changes versus FY2022
| Segment | Revenue | Change | Operating income / margin |
|---|---|---|---|
| Research Models and Services (RMS) | $792.3 million | +7.2% | $154.7 million / 19.5%, versus 21.7% |
| Discovery and Safety Assessment (DSA) | $2.616 billion | +6.9% | $606.1 million / 23.2%, versus 21.8% |
| Manufacturing Solutions | $721.4 million | -8.6% | $88.3 million / 12.2%, versus 21.2% |
- RMS growth reflected research-model services, small-model sales and acquisitions, including Explora BioLabs; higher costs and unfavorable mix reduced segment margin.
- DSA benefited from Safety Assessment demand and pricing, while Discovery Services demand weakened as clients reprioritized programs. DSA backlog declined to $2.45 billion from $3.15 billion.
- Manufacturing revenue and operating income were affected by the 2022 Avian Vaccine Services divestiture, weaker Biologics Testing revenue, restructuring and higher Biologics costs. The prior-year period also included a $19 million favorable indirect-tax ruling.
- Year-end backlog was approximately $489 million in RMS, $2.5 billion in DSA and $143 million in Manufacturing. The company cautions that backlog may be delayed, changed or canceled and is not necessarily predictive of future revenue.
Outlook, commentary and material risks
- Management described cautious client spending amid weaker biotechnology funding, higher interest rates and broader market uncertainty. Large biopharmaceutical clients remained the principal growth driver; small and mid-sized biotechnology demand moderated.
- Restructuring charges were approximately $29.7 million in FY2023, including $18.1 million of asset impairments and other costs and $11.6 million of severance and transition costs. Management expects completed and planned actions to generate approximately $60–$70 million in annualized cost savings.
- The filing does not provide a clear numerical FY2024 revenue or earnings guidance figure. Management expresses a longer-term view that outsourcing and demand for integrated research services remain supportive, while acknowledging near-term uncertainty.
- Non-human primate sourcing is a significant legal, operational and supply risk. The company suspended future Cambodia-to-U.S. shipments pending agreement on additional procedures. DOJ/USFWS investigations and an SEC inquiry are ongoing; the company says it cannot predict outcomes or potential penalties. Inventory from specified Cambodia shipments had a carrying value of approximately $27 million at year-end.
- A securities class action and a derivative lawsuit relating to disclosures about non-human primate sourcing are pending. The company disputes the claims; potential exposure cannot be reasonably estimated.
- Other key risks include constrained non-human-primate supply and higher costs; volatility in client R&D budgets and credit losses (allowance rose to $25.7 million from $11.3 million); competition and alternative non-animal methods; contract cancellations and cost overruns; regulatory compliance; cybersecurity; foreign exchange; and leverage.
- Unusual items affected comparability: Noveprim acquisition accounting generated a $98.5 million gain, while FY2022 included a $123.4 million gain on the Avian divestiture and $49.7 million of gains tied to a debt-related currency forward contract. Interest expense increased to $136.7 million, principally reflecting higher rates and the absence of the prior-year forward-contract gains.
- The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; management also concluded controls were effective. Noveprim was excluded from the FY2023 internal-control assessment because it was acquired during the year.
Important facts for investors to verify
- Progress, duration and potential financial consequences of the DOJ/USFWS investigations, SEC inquiry and related lawsuits.
- Whether the company can restore or diversify non-human-primate supply and implement purpose-bred sourcing procedures.
- Whether DSA backlog conversion and Safety Assessment demand offset continued weakness in Discovery Services and biotechnology spending.
- Whether Manufacturing performance improves and the announced restructuring savings are realized without further impairment or execution costs.
- Debt, interest expense, covenant headroom and cash needs for capital spending, acquisitions and purchase commitments.
- How much of reported earnings reflects acquisition-related and other unusual gains or charges, and the continuing rise in the allowance for credit losses.